Novo Nordisk CEO Discloses 4,000 Additional Departures, Layoffs Reach 13,000

The scale here is the story: a restructuring that keeps deepening while the company simultaneously redraws its reporting lines around a new Blood and Endocrine Diseases segment. That combination — cutting headcount and reorganizing around liver and cardiovascular expansion — signals a portfolio being narrowed toward higher-conviction bets rather than broad-based retrenchment. The open question is whether the departures stabilize once the integration is complete, or whether the new segment structure invites further consolidation.